Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics Inc (NQ: CGTX )

1.940 +0.110 (+6.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 70,098
Open 1.790
Bid (Size) 1.840 (5)
Ask (Size) 1.930 (4)
Prev. Close 1.830
Today's Range 1.790 - 1.960
52wk Range 1.070 - 6.269
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
-5.37%
-5.37%
1 Month
+28.05%
+28.05%
3 Month
-7.62%
-7.62%
6 Month
+13.45%
+13.45%
1 Year
-36.18%
-36.18%

More News

Read More
Cognition Therapeutics's Earnings: A Preview
Via Benzinga
Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023
From Cognition Therapeutics, Inc.
Via Globe NewsWire
UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference
From Cognition Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"
From Cognition Therapeutics, Inc.
Via Globe NewsWire
First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812
From Cognition Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Okta Shares Are Trading Higher By Around 14%; Here Are 27 Stocks Moving Premarket
Via Benzinga
Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD
From Cognition Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Why Richardson Electronics Shares Surged Over 8%; Here Are 55 Biggest Movers From Friday
Via Benzinga
$1.8 Million Bet On Cognition Therapeutics? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Cognition Therapeutics Announces Closing of Public Offering
From Cognition Therapeutics, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.